Recent Advances in the Prevention of RSV in Neonates and Young Infants

키워드

참고문헌 (48)

1. Shi T, "Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015 : a systematic review and modelling study", Lancet, 390, pp.946~958 (2017)
2. Mejias A, "The journey to a respiratory syncytial virus vaccine", Ann Allergy Asthma Immunol, 125, pp.36~46 (2020)
3. Magro M, "Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention", Proc Natl Acad Sci U S A, 109, pp.3089~3094 (2012)
4. Flynn JA, "Stability characterization of a vaccine antigen based on the respiratory syncytial virus fusion glycoprotein", PLoS One, 11, pp.e0164789~ (2016)
5. "RSV vaccine and mAb snapshot" (2023)[URL]
6. Simões EA, "The burden of respiratory syncytial virus lower respiratory tract disease in infants in the United States : a synthesis", J Infect Dis, 226(Suppl 2), pp.S143~S147 (2022)
7. Thomas E, "Burden of respiratory syncytial virus infection during the first year of life", J Infect Dis, 223, pp.811~817 (2021)
8. Kang JM, "Pediatric intensive care unit admission due to respiratory syncytial virus : Retrospective multicenter study", Pediatr Int, 61, pp.688~696 (2019)
9. Yun KW, "Molecular epidemiology of respiratory syncytial virus for 28 consecutive seasons(1990–2018)and genetic variability of the duplication region in the G gene of genotypes ON1 and BA in South Korea", Arch Virol, 165, pp.1069~1077 (2020)
10. Kim Ye Kyung, "Shift in Clinical Epidemiology of Human Parainfluenza Virus Type 3 and Respiratory Syncytial Virus B Infections in Korean Children Before and During the COVID-19 Pandemic: A Multicenter Retrospective Study", Journal of Korean Medical Science, 37(28), pp.1~9 (2022), 대한의학회[DOI]
11. The IMpact-RSV Study Group, "Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants", Pediatrics, 102, pp.531~537 (1998)
12. Feltes TF, "Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease", J Pediatr, 143, pp.532~540 (2003)
13. Lee JH, "Respiratory syncytial virus related readmission in preterm infants less than 34 weeks’ gestation following discharge from a neonatal intensive care unit in Korea", J Korean Med Sci, 1(Suppl 1), pp.S104~S110 (2015)
14. Andabaka T, "Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children", Cochrane Database Syst Rev, pp.CD006602~ (2013)
15. Paes BA, "Caress investigators. Respiratory syncytial virus prophylaxis in immunocompromised children : outcomes from the Canadian RSV evaluation study of palivizumab registry over twelve seasons(2005-2017)", Pediatr Infect Dis J, 39, pp.539~545 (2020)
16. Wang DY, "Respiratory syncytial virus prophylaxis in neurologic and muscular disorders in the Canadian respiratory syncytial virus evaluation study of palivizumab", Pediatr Infect Dis J, 38, pp.775~780 (2019)
17. 김승연, "Respiratory Syncytial Virus 유행 시기에 따른Palivizumab 예방요법시기의 적정성 평가: 22년간단일기관 연구", Pediatric Infection and Vaccine, 22(3), pp.172~177 (2015), 대한소아감염학회
18. Zhu Q, "A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants", Sci Transl Med, 9, pp.eaaj1928~ (2017)
19. Griffin MP, "Single-dose nirsevimab for prevention of RSV in preterm infants", N Engl J Med, 383, pp.415~425 (2020)
20. Hammitt LL, "Nirsevimab for prevention of RSV in healthy late-preterm and term infants", N Engl J Med, 386, pp.837~846 (2022)
21. Domachowske J, "Safety of nirsevimab for RSV in infants with heart or lung disease or prematurity", N Engl J Med, 386, pp.892~894 (2022)
22. Tang A, "A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein", Nat Commun, 10, pp.4153~ (2019)
23. Simões EA, "Suptavumab for the prevention of medically attended respiratory syncytial virus infection in preterm infants", Clin Infect Dis, 73, pp.e4400~e4408 (2021)
24. Langedijk AC, "A systematic review on global RSV genetic data : Identification of knowledge gaps", Rev Med Virol, 32, pp.e2284~ (2022)
25. Zhu Q, "Prevalence and significance of substitutions in the fusion protein of respiratory syncytial virus resulting in neutralization escape from antibody MEDI8897", J Infect Dis, 218, pp.572~580 (2018)
26. Oliveira DB, "Molecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab immunoprophylaxis", J Clin Virol, 65, pp.26~31 (2015)
27. Choi SH, "Analysis of respiratory syncytial virus fusion protein from clinical isolates of Korean children in palivizumab era, 2009-2015", J Infect Chemother, 25, pp.514~519 (2019)
28. Kim HW, "Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine", Am J Epidemiol, 89, pp.422~434 (1969)
29. Kapikian AZ, "An epidemiologic study of altered clinical reactivity to respiratory syncytial(RS)virus infection in children previously vaccinated with an inactivated RS virus vaccine", Am J Epidemiol, 89, pp.405~421 (1969)
30. Albrecht M, "Vertically transferred immunity in neonates : mothers, mechanisms and mediators", Front Immunol, 11, pp.555~ (2020)
31. Buchwald AG, "Respiratory syncytial virus(RSV)neutralizing antibodies at birth predict protection from RSV illness in infants in the first 3 months of life", Clin Infect Dis, 73, pp.e4421~e4427 (2021)
32. Roca A, "Prevalence of respiratory syncytial virus IgG antibodies in infants living in a rural area of Mozambique", J Med Virol, 67, pp.616~623 (2002)
33. Munoz FM, "Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women", Vaccine, 21, pp.3465~3467 (2003)
34. Koivisto K, "Respiratory Syncytial Virus(RSV)-specific antibodies in pregnant women and subsequent risk of RSV hospitalization in young infants", J Infect Dis, 225, pp.1189~1196 (2022)
35. Glenn GM, "A randomized, blinded, controlled, dose-ranging study of a respiratory syncytial virus recombinant fusion(F)nanoparticle vaccine in healthy women of childbearing age", J Infect Dis, 213, pp.411~422 (2016)
36. Muňoz FM, "Safety and immunogenicity of a respiratory syncytial virus fusion(F)protein nanoparticle vaccine in healthy third-trimester pregnant women and their infants", J Infect Dis, 220, pp.1802~1815 (2019)
37. Madhi SA, "Respiratory syncytial virus vaccination during pregnancy and effects in infants", N Engl J Med, 383, pp.426~439 (2020)
38. Beran J, "Safety and immunogenicity of 3 formulations of an investigational respiratory syncytial virus vaccine in nonpregnant women : results from 2 phase 2 trials", J Infect Dis, 217, pp.1616~1625 (2018)
39. Schwarz TF, "Immunogenicity and safety of 3 formulations of a respiratory syncytial virus candidate vaccine in nonpregnant women : a phase 2, randomized trial", J Infect Dis, 220, pp.1816~1825 (2019)
40. Walsh EE, "A randomized phase 1", 2 study of a respiratory syncytial virus prefusion F vaccine, 2022, pp.225, 1357~1366
41. Simões EA, "Prefusion F protein-based respiratory syncytial virus immunization in pregnancy", N Engl J Med, 386, pp.1615~1626 (2022)
42. Wright PF, "The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines", Vaccine, 25, pp.7372~7378 (2007)
43. Buchholz UJ, "Live respiratory syncytial virus(RSV)vaccine candidate containing stabilized temperature-sensitivity mutations is highly attenuated in RSV-seronegative infants and children", J Infect Dis, 217, pp.1338~1346 (2018)
44. McFarland EJ, "Live-attenuated respiratory syncytial virus vaccine candidate with deletion of RNA synthesis regulatory protein M2-2 is highly immunogenic in children", J Infect Dis, 217, pp.1347~1355 (2018)
45. McFarland EJ, "Live respiratory syncytial virus attenuated by M2-2 deletion and stabilized temperature sensitivity mutation 1030s is a promising vaccine candidate in children", J Infect Dis, 221, pp.534~543 (2020)
46. Williams K, "Phase 1 safety and immunogenicity study of a respiratory syncytial virus vaccine with an adenovirus 26 vector encoding prefusion F(Ad26. RSV. preF)in adults aged ≥60 years", J Infect Dis, 222, pp.979~988 (2020)
47. Sadoff J, "Prevention of respiratory syncytial virus infection in healthy adults by a single immunization of Ad26. RSV. preF in a human challenge study", J Infect Dis, 226, pp.396~406 (2022)
48. Aliprantis AO, "A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults", Hum Vaccin Immunother, 17, pp.1248~1261 (2021)

관련 논문AI추천